Clinical Trials Register

Summary
EudraCT Number:	2014-005251-39
Sponsor's Protocol Code Number:	PM1183-C-004-14
National Competent Authority:	France - ANSM
Clinical Trial Type:	EEA CTA
Trial Status:	Completed
Date on which this record was first entered in the EudraCT database:	2016-01-21
Trial results	View results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

France - ANSM

A.2

EudraCT number

2014-005251-39

A.3

Full title of the trial

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)

Étude clinique de phase III, randomisée, comparant la lurbinectédine (PM01183) à la doxorubicine liposomale pégylée ou au topotécan chez des patientes présentant un cancer de l’ovaire résistant au platine (Etude CORAIL)

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

Clinical Trial of Lurbinectedin versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer

Étude clinique comparant la lurbinectédine à la doxorubicine liposomale pégylée ou au topotécan chez des patientes présentant un cancer de l’ovaire résistant au platine

A.3.2

Name or abbreviated title of the trial where available

CORAIL Trial

Etude CORAIL

A.4.1

Sponsor's protocol code number

PM1183-C-004-14

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Pharma Mar S.A., Sociedad Unipersonal
B.1.3.4	Country	Spain
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Pharma Mar S.A., Sociedad Unipersonal
B.4.2	Country	Spain
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Pharma Mar S.A., Sociedad Unipersonal
B.5.2	Functional name of contact point	Clinical Trials
B.5.3	Address:
B.5.3.1	Street Address	Av. de los Reyes, 1. Pol. Ind. "La Mina"
B.5.3.2	Town/ city	Colmenar Viejo, Madrid
B.5.3.3	Post code	28770
B.5.3.4	Country	Spain
B.5.4	Telephone number	3491846 6077
B.5.5	Fax number	3491846 6003
B.5.6	E-mail	cmfernandez@pharmamar.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	Yes
D.2.5.1	Orphan drug designation number	EU/3/12/1053
D.3 Description of the IMP
D.3.1	Product name	Lurbinectedin
D.3.2	Product code	PM01183
D.3.4	Pharmaceutical form	Powder for concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	LURBINECTEDIN
D.3.9.1	CAS number	497871-47-3
D.3.9.2	Current sponsor code	PM01183
D.3.9.3	Other descriptive name	LURBINECTEDIN
D.3.9.4	EV Substance Code	SUB31196
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	1
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	Caelyx 2 mg/ml concentrate for solution for infusion
D.2.1.1.2	Name of the Marketing Authorisation holder	Janssen-Cilag International NV
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	pegylated liposomal doxorubicin hydrochloride
D.3.4	Pharmaceutical form	Concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	doxorubicin
D.3.9.1	CAS number	C50664300
D.3.9.3	Other descriptive name	PEGYLATED LIPOSOMAL DOXORUBICIN
D.3.9.4	EV Substance Code	SUB33393
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	2
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No
D.IMP: 3
D.1.2 and D.1.3	IMP Role	Comparator
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	topotecan hydrochloride
D.3.4	Pharmaceutical form	Powder for concentrate for solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	topotecan
D.3.9.1	CAS number	123948-87-8
D.3.9.4	EV Substance Code	SUB11191MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	4
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Platinum-resistant ovarian cancer

Cancer de l’ovaire résistant au platine

E.1.1.1

Medical condition in easily understood language

ovarian cancer

Cancer de l’ovaire

E.1.1.2

Therapeutic area

Diseases [C] - Cancer [C04]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	18.1
E.1.2	Level	LLT
E.1.2	Classification code	10033130
E.1.2	Term	Ovarian cancer NOS
E.1.2	System Organ Class	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

E.1.2 Medical condition or disease under investigation

E.1.2	Version	18.1
E.1.2	Level	PT
E.1.2	Classification code	10033128
E.1.2	Term	Ovarian cancer
E.1.2	System Organ Class	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

To determine a difference in progression-free-survival (PFS) between lurbinectedin (PM01183) and pegylated liposomal doxorubicin (PLD) or topotecan in platinum-resistant ovarian cancer patients according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.

Déterminer une différence dans la survie sans progression (PFS) entre la lurbinectédine (PM01183) et la doxorubicine liposomale pégylée (DLP) ou le topotécan chez des patientes présentant un cancer de l’ovaire résistant au platine selon les critères d'évaluation de réponse des tumeurs solides (RECIST) v. 1.1.

E.2.2

Secondary objectives of the trial

To evaluate:
- Overall survival (OS).
- Antitumor activity.
- Safety profile.
- Patient-reported outcomes (PRO).

To characterize the plasma pharmacokinetics (PK) of PM01183 using a sparse sampling scheme in the PM01183 treatment arm (Arm A).

Subgroup analyses of the PM01183 arm versus PLD or topotecan.

To conduct an exploratory pharmacogenetic and pharmacogenomic (PGx) sub-study.

Évaluer:
• La survie globale (OS).
• L’activité antitumorale.
• Le profil de sécurité.
• Les résultats rapportés par la patiente (PRO).

Caractériser la pharmacocinétique plasmatique (PK) du PM01183 en utilisant un plan d'échantillonnage épars dans le bras de traitement PM01183 (Bras A).

Analyses de sous-groupe du bras PM01183 versus DLP ou topotécan.
Conduire une sous-étude pharmacogénétique et pharmacogénomique (PGx) exploratoire.

E.2.3

Trial contains a sub-study

Yes

E.2.3.1

Full title, date and version of each sub-study and their related objectives

PHARMACOGENETIC EVALUATIONS - To explore factors that may help to explain individual variability in main pharmacokinetic (PK) parameters, the presence or absence of germline mutations or polymorphisms will be analyzed in leukocyte DNA extracted from a blood sample obtained before treatment start in the PM01183 arm (Arm A).

PHARMACOGENOMIC EVALUATIONS - The analysis of potential predictive factors to PM01183 treatment will be analyzed on prior available paraffin-embedded tumor tissue samples from consenting patients.

ÉVALUATIONS DE PHARMACOGENETIQUE
Afin d'étudier les facteurs susceptibles d'expliquer la variabilité individuelle des principaux paramètres pharmacocinétiques (PK), on analysera la présence ou l'absence de mutations ou de polymorphismes de la lignée germinale dans l'ADN leucocytaire extrait d'un échantillon sanguin obtenu avant le début du traitement dans le groupe PM01183 (Bras A).

ÉVALUATIONS PHARMACOGÉNOMIQUES
L'analyse de facteurs prédictifs potentiels du traitement par PM01183 sera effectuée sur des échantillons disponibles de tissu tumoral inclus en paraffine provenant de patientes ayant donné leur consentement.

E.3

Principal inclusion criteria

1) Voluntary written informed consent (IC) of the patient obtained before any study-specific procedure.
2) Age ≥ 18 years.
3) Histologically or cytologically confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.
4) Platinum-resistant disease (PFI: 1-6 months after last platinum-containing chemotherapy).
5) Radiologically measurable and/or non-measurable progressive disease according to RECIST v 1.1.
6) No more than three prior systemic chemotherapy regimens. Note: in case that a patient had started a new systemic chemotherapy without disease progression to the prior chemotherapy line (e.g., treatment discontinuations due to toxicity; neoadjuvant followed by adjuvant chemotherapy regimens), these two chemotherapy regimens will considered as one.
7) ECOG PS ≤ 2.
8) Adequate hematological, renal, metabolic and hepatic function:
a) Hemoglobin ≥ 9 g/dl [patients may have received prior red blood cell (RBC) transfusion]; absolute neutrophil count (ANC) ≥ 2.0 x 109/l, and platelet count ≥ 100 x 109/l.
b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x upper limit of normal (ULN).
c) Alkaline phosphatase (AP) < 5.0 x ULN.
d) Total bilirubin ≤ ULN or direct bilirubin ≤ ULN if total bilirubin is > ULN.
e) Albumin ≥ 3.0 g/dl.
f) Calculated creatinine clearance (CrCL) ≥ 30 ml/min (using Cockcroft and Gault's formula).
g) Creatine phosphokinase (CPK) ≤ 2.5 x ULN.
9) At least three weeks since last prior therapy, and grade ≤ 1 from any adverse event (AE) derived from previous treatment (excluding grade ≤ 2 alopecia or peripheral neuropathy) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v. 4).
10) Women of childbearing potential must have pregnancy excluded by appropriate testing before study entry. A medically acceptable method of contraception must be maintained throughout the treatment period and for at least six months after treatment discontinuation.

1) Consentement éclairé (CE) écrit volontaire de la patiente obtenu avant toute procédure spécifique de l'étude.
2) Âge ≥ 18 ans.
3) Diagnostic confirmé par histologie ou cytologie de cancer épithélial de l'ovaire, de cancer des trompes de Fallope ou de cancer péritonéal primaire, non résécable.
4) Maladie résistante au platine (PFI : 1-6 mois après la dernière chimiothérapie à base de platine).
5) Maladie progressive mesurable et/ou non mesurable radiologiquement selon les critères RECIST v. 1.1.
6) Pas plus de 3 protocoles de chimiothérapie systémique antérieurs. Remarque : si une patiente a commencé une nouvelle chimiothérapie systémique sans progression de la maladie suite à la ligne de chimiothérapie précédente (par ex. arrêts de traitement dus à une toxicité ; chimiothérapie néoadjuvante suivie d’une chimiothérapie adjuvante), ces deux protocoles de chimiothérapie seront considérés comme un protocole unique.
7) PS ECOG ≤ 2.
8) Fonctions hématologique, rénale, métabolique et hépatique adéquates :
a) Hémoglobine ≥ 9 g/dl [les patientes peuvent avoir reçu antérieurement une transfusion de globules rouges (GR)] ; numération absolue des neutrophiles (ANC) ≥ 2,0 x 109/l, et numération plaquettaire ≥ 100 x 109/l.
b) Alanine aminotransférase (ALT) et aspartate aminotransférase (AST) ≤ 3,0 x limite supérieure de la normale (LSN).
c) Phosphatase alcaline (PA) < 5,0 x LSN.
d) Bilirubine totale ≤ LSN ou bilirubine directe ≤ LSN si la bilirubine totale est > LSN.
e) Albumine ≥ 3,0 g/dl.
f) Clairance de la créatinine (ClCr) calculée ≥ 30 ml/min (en utilisant la formule de Cockcroft et Gault).
g) Créatine phosphokinase (CPK) ≤ 2,5 x LSN.
9) Au moins 3 semaines depuis le dernier traitement antérieur, et grade ≤ 1 pour tout événement indésirable (EI) lié au traitement antérieur (à l’exclusion d’une alopécie ou d’une neuropathie périphérique de grade ≤ 2) selon les critères de terminologie commune des événements indésirables du National Cancer Institute (NCI-CTCAE v. 4).
10) Les femmes en âge de procréer doivent faire un test de grossesse avant l'inclusion dans l'étude afin d'exclure une grossesse. Une méthode contraceptive médicalement acceptable doit être suivie pendant toute la durée du traitement et pendant au moins 6 mois après l'arrêt du traitement.

E.4

Principal exclusion criteria

1) Concomitant diseases/conditions:
a) History of cardiac disease: myocardial infarction or symptomatic/uncontrolled angina within the year prior to enrollment; or congestive heart failure defined as abnormal left ventricular ejection fraction (LVEF) < 50% assessed by multiple-gated acquisition scan (MUGA) or equivalent by ultrasound (US); or symptomatic arrhythmia.
b) Patients with any immunodeficiency, including those known to be infected by human immunodeficiency virus (HIV).
c) Chronic active hepatitis or cirrhosis. For Hepatitis B, this includes positive tests for both Hepatitis B surface antigen and quantitative Hepatitis B polymerase chain reaction (PCR). For Hepatitis C, this includes positive tests for both Hepatitis C antibody and quantitative Hepatitis C PCR.
d) Active uncontrolled infection.
e) Bowel obstruction.
f) Requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomization.
g) Limitation of the patient's ability to comply with the treatment or to follow-up the protocol.
h) Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.
2) Platinum-refractory or platinum-sensitive disease (PFI <1 or > 6 months).
3) Prior treatment with PM01183, trabectedin, or with both PLD and topotecan.
Note: if 60% of recruitment is reached in one of the control treatment options (i.e., PLD or topotecan), patients could only be eligible if they did not previously receive the other control treatment option available (the Sponsor will inform the sites, if this occurs).
4) Known brain metastases or leptomeningeal disease involvement.
5) History of another neoplastic disease (except for curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or properly treated carcinoma in situ of the uterine cervix or breast) within three years prior to randomization.
6) Pregnant or breast feeding women.

1) Maladies/ affections concomitantes :
a) Antécédents de maladie cardiaque : infarctus du myocarde ou angor symptomatique/ non contrôlé dans l'année qui précède l’inclusion ; ou insuffisance cardiaque congestive définie comme une fraction d'éjection ventriculaire gauche (FEVG) anormale < 50 %, évaluée par MUGA ou par échographie ; ou arythmie symptomatique.
b) Patientes présentant toute immunodéficience, notamment patientes présentant une infection par le virus de l'immunodéficience humaine (VIH) connue.
c) Hépatite chronique active ou cirrhose. Pour l'hépatite B, cela comprend des résultats positifs pour l'antigène de surface du VHB et pour l’analyse quantitative de VHB par PCR (amplification en chaîne par polymérase). Pour le virus de l'hépatite C, cela comprend des résultats positifs pour les anticorps anti-VHC et pour l’analyse quantitative de VHC par PCR.
d) Infection active non contrôlée.
e) Obstruction intestinale.
f) Nécessité de drainage externe permanent ou fréquent (c'est-à-dire une fois par semaine) dans les 2 semaines qui précèdent la randomisation.
g) Capacité limitée pour la patiente de se conformer au traitement ou au respect du protocole.
h) Toute autre maladie majeure qui, selon le jugement de l'investigateur, augmenterait significativement les risques associés à la participation de la patiente à l'étude.
2) Maladie résistante au platine ou sensible au platine (PFI < 1 mois ou > 6 mois).
3) Traitement antérieur avec le PM01183, la trabectédine, ou avec la DLP et le topotécan.
Remarque : si 60 % du recrutement est atteint dans une des options de traitement contrôle (DLP ou topotécan), les patientes ne peuvent être éligibles que si elles n'ont pas bénéficié antérieurement de l'autre option de traitement contrôle disponible (le cas échéant, le promoteur en informera les centres).
4) Présence connue de métastases cérébrales ou d'atteinte leptoméningée.
5) Antécédents d'autres maladies néoplasiques (à l'exception d'un carcinome basocellulaire guéri, d'un carcinome épithélioïde de la peau guéri, ou d'un carcinome in situ du col de l'utérus ou du sein correctement traité) dans les trois ans qui précèdent la randomisation.
6) Femme enceinte ou allaitante.

E.5 End points

E.5.1

Primary end point(s)

Progression-free survival (PFS)

Survie sans Progression (PFS)

E.5.1.1

Timepoint(s) of evaluation of this end point

Along the study

Tout au mong de l'étude

E.5.2

Secondary end point(s)

- Progression-free survival (PFS)
- Overall survival (OS)
- Landmark analyses:
o PFS at 6 and 12 months by IRC/IA
o OS at 12 and 24 months
- Best antitumor response by IRC/IA
- Duration of response (DR) by IRC/IA
- Best response according to tumor marker evaluation (CA-125)
- Treatment safety profile
- Patient-reported outcomes (PRO):
- Plasma pharmacokinetics (PK) of PM01183
- Subgroup analyses: Subgroup analyses of the PM01183 arm versus PLD or topotecan
- Pharmacogenetics
- Pharmacogenomics

- La Survie sans progression (PFS)
- La Survie globale (OS)
- Analyses clés :
o Les PFS à 6 et 12 mois selon l’IRC/IA
o Les OS à 12 et 24 mois
- La meilleure réponse antitumorale selon l’IRC/IA
- La durée de la réponse (DR) selon l’IRC/IA
- La meilleure réponse selon l'évaluation du marqueur tumoral (CA-125)
- Profil de sécurité du traitement
- Résultats rapportés par la patiente (PRO)
- La pharmacocinétique (PK) plasmatique du PM01183
- Analyses de sous-groupe
- Pharmacogénétique
- Pharmacogénomique

E.5.2.1

Timepoint(s) of evaluation of this end point

Along the study

Tout au long de l'étude

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

Yes

E.6.10

Pharmacogenetic

Yes

E.6.11

Pharmacogenomic

Yes

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

E.7.3

Therapeutic confirmatory (Phase III)

Yes

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

Yes

E.8.1.3

Single blind

E.8.1.4

Double blind

E.8.1.5

Parallel group

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

Yes

E.8.2.2

Placebo

E.8.2.3

Other

Yes

E.8.2.3.1

Comparator description

Doxorubicine liposomale pégylée (PLD) ou topotécan

Pegylated liposomal doxorubicin hydrochloride (PLD) or topotecan

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

Yes

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Austria

Belgium

Bulgaria

Czech Republic

France

Germany

Hungary

Italy

Romania

Serbia

Spain

United Kingdom

United States

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

24 months after randomization of the last patient.

24 mois après la randomisation du dernier patient

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

294

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

126

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

265

F.4.2.2

In the whole clinical trial

420

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

None

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2015-11-04

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2015-11-03

P. End of Trial
P.	End of Trial Status	Completed
P.	Date of the global end of the trial	2018-10-12

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials